Abstract
Background & Aims: Chronic hepatitis B (CHB) infection can cause liver cirrhosis and hepatocellular carcinoma. In this study, it was aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) on clinical parameters, glomerular filtration rate (GFR), and phosphorus metabolism in the patients with CHB. 
 Materials and Methods: Eighty-one patients with CHB treated with TDF were included in the study. 27 of them switched from TDF to TAF during the follow-up was considered as TAF group. 54 patients continued TDF were evaluated as TDF group. Demographic, clinical, and laboratory data of the patients were obtained from outpatient follow-up files.
 Results: The mean ages of the patients were 45±12 and 48±15 in the TDF and TAF groups, respectively. The mean durations of TDF treatment were 31±20 and 52±32 months, respectively. The mean duration of TDF use was significantly higher in the TAF group (0.01). The mean aspartate aminotransferase (AST), alanine aminotransferase (ALT), GFR, and serum phosphorus levels of the patients before/after the TDF treatment were 48/23 U/L, 67/25 U/L, 99/103 ml/min, and 2.9/3.1 mg/dl in the TDF group, respectively. The mean AST, ALT, GFR, and serum phosphorus levels of the patients before the TDF treatment/at the time of the switch/after the TAF treatment were 42/22/21 U/L, 48/23/22 U/L, 90/100/102 ml/min, and 2.8/2.3/2.9 mg/dl in the TAF group, respectively. Decrease in the mean values of the transaminases after the TDF treatment in the both groups and increase in the mean level of phosphorus after the switching were found significant (p
Highlights
It is estimated that approximately 257 million people worldwide are chronically infected with hepatitis B virus, which is one of the major causes of chronic liver disease, liver cirrhosis, and hepatocellular carcinoma (HCC) [13]
It was aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) on clinical parameters, glomerular filtration rate (GFR), and phosphorus metabolism in the patients with Chronic hepatitis B (CHB)
Five patients switched from TDF to TAF were excluded in the hypophosphatemia group
Summary
It is estimated that approximately 257 million people worldwide are chronically infected with hepatitis B virus, which is one of the major causes of chronic liver disease, liver cirrhosis, and hepatocellular carcinoma (HCC) [13]. In these patients, the level of viral load in the serum and the risk of developing liver cirrhosis, HCC, and other liver-related complications are directly related [4]. In 5 years with entecavir, the resistance rate found in naive patients was 1.2%, while this rate was 51% in lamivudine-resistant patients [8,9] For this reason, drugs with higher resistance barriers have been developed over time. Tenofovir disoproxil fumarate (TDF), which has been used for CHB since 2008, has a very high resistance barrier and no resistance has been
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call